RVNC Revance Therapeutics Inc.

13.25
-0.24  -2%
Previous Close 13.49
Open 13.53
Price To Book 4
Market Cap 583394824
Shares 44,029,798
Volume 161,126
Short Ratio
Av. Daily Volume 374,726

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completion of enrolment due 2H 2019.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 3 completion of enrolment due 2H 2019.
RT002 - ASPEN
Cervical dystonia
BLA filing due 1H 2019.
RT002
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated 2019.
RT002
Chronic migraine
Phase 2 completion of enrolment due 2H 2019.
RT002
Upper limb spasticity

Latest News

  1. Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing
  2. SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference
  3. Maker of Botox alternative turns toxin on crippling muscle disorder
  4. Revance to Participate in the Needham Healthcare Conference
  5. Does Revance Therapeutics, Inc. (NASDAQ:RVNC) Have A Volatile Share Price?
  6. New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  7. Revance to Participate in Upcoming Investor Conferences
  8. Edited Transcript of RVNC earnings conference call or presentation 26-Feb-19 9:30pm GMT
  9. Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018
  10. Need To Know: Revance Therapeutics, Inc. (NASDAQ:RVNC) Insiders Have Been Buying Shares
  11. Revance Therapeutics Inc (RVNC) Q4 2018 Earnings Conference Call Transcript
  12. Revance Releases Fourth Quarter and Full Year 2018 Results
  13. Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
  14. CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
  15. Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
  16. What Kind Of Shareholders Own Revance Therapeutics, Inc. (NASDAQ:RVNC)?
  17. Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics — Discovering Underlying Factors of Influence
  18. Revance Announces Closing of Public Offering of Common Stock
  19. Revance Announces Pricing of Public Offering of Common Stock
  20. The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen